FIELD: medical biotechnology.
SUBSTANCE: disclosed is the use of a fused protein, containing recovered recombinant human soluble ectonucleotide pyrophosphatase/phosphodiesterase (sNPP1) and Fc region of immunoglobulin, a pharmaceutical composition containing said fusion protein, in preparing a drug for treating elastic pseudoxanthoma (PXE). What is declared is the use of the fusion protein in preparing a drug for treating NPP1 deficiency or a disease associated with NPP1.
EFFECT: invention provides a therapy for effective inhibition of vascular calcification, preferably without causing osteomalacia; also enables to obtain an effective and safe drug for treating IIAC, vascular calcification in chronic kidney disease (VCCKD), elastic pseudoxanthoma (PXE), insulin resistance, hypophosphatemic rickets and ossification of the posterior longitudinal ligament of the spine.
24 cl, 2 tbl, 33 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS OF CALCIFICATION AND THEIR APPLICATION METHODS | 2016 |
|
RU2757417C2 |
| NPP1 FUSION PROTEINS | 2011 |
|
RU2760943C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| TREATMENT OF MUSCULAR WEAKNESS WITH ALKALINE PHOSPHATASES | 2017 |
|
RU2754558C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
